Fractyl Health (NASDAQ:GUTS) & Nuvilex (NASDAQ:PMCB) Head-To-Head Contrast

Fractyl Health (NASDAQ:GUTS) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Valuation and Earnings

This table compares Fractyl Health and Nuvilex”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90,000.00	1,330.90	-$140.95 million	($1.29)	-0.59
Nuvilex	N/A	N/A	$30.66 million	($1.12)	-0.55

Nuvilex has lower revenue, but higher earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Fractyl Health has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Profitability

This table compares Fractyl Health and Nuvilex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-4,053.15%	-96.41%
Nuvilex	N/A	2.13%	1.69%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Fractyl Health and Nuvilex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1	1	4	0	2.50
Nuvilex	1	0	0	0	1.00

Fractyl Health currently has a consensus target price of $5.12, suggesting a potential upside of 578.15%. Given Fractyl Health’s stronger consensus rating and higher possible upside, analysts plainly believe Fractyl Health is more favorable than Nuvilex.

Institutional & Insider Ownership

34.2% of Nuvilex shares are held by institutional investors. 8.5% of Fractyl Health shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Nuvilex beats Fractyl Health on 7 of the 12 factors compared between the two stocks.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.